Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Drugs registered on...

    Drugs registered on SUGAM portal to be exempted from obtaining licence for purpose of examination, test, analysis

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-04-21T14:26:36+05:30  |  Updated On 17 Aug 2021 10:57 AM IST

    The exemption from obtaining a licence for Form 29 is subject to the condition that the information about the manufacturing of approved drugs for examination, test or analysis shall be uploaded on the SUGAM Portal.


    New Delhi: In a major relief to drug manufacturers, the Government will soon amend the Drugs and Cosmetics Rule to exempt drug manufacturers from obtaining a licence in Form 29 for the manufacture of approved drugs who are already holding a licence in Form 25/Form 28 to manufacture any drug in the same dosage form.


    The matter was deliberated in the 82nd meeting of Drugs Technical Advisory Board (DTAB) wherein the board was apprised that, licence to manufacture drugs for the purposes of examination, test or analysis is granted in Form 29 under Rule 89 of the Drugs and Cosmetics Rules, 1945 and licence to manufacture of drugs for sale or for distribution is granted in Form 25 or Form 28 under the said rules.


    Rule 89 of the Drugs and Cosmetics Rules, 1945 is reproduced below:-




    "89. Licence.–If the person proposing to manufacture a drug for the purpose of examination, test or analysis does not hold a licence in Form 25 or Form 28 in respect of such drugs he shall, before commencing such manufacture, obtain a licence in Form 29."



    Also Read: Information about licenses to be uploaded on online portal SUGAM: Health Ministry Gazette


    It was proposed to exempt for obtaining a licence in Form 29 for the manufacture of approved drugs for the purposes of examination, test or analysis by the manufactures who are already holding valid product permission for manufacturing of same dosage form of any drug in Form 25 or Form 28.


    DTAB examined the proposal in detail and agreed to exempt for obtaining licence in Form 29 for manufacture of approved drugs by the manufacturers who are already holding licence in Form 25/Form 28 to manufacture any drug in same dosage form subject to the condition that the information about the manufacturing of such drugs for examination, test or analysis shall be uploaded on the SUGAM Portal.


    Accordingly, the Drugs and Cosmetics Rules shall be amended.


    Medical Dialogues had earlier reported that through Gazette notification, the Ministry of Health and Family Welfare had amended the Drugs and Cosmetics Rules, 1945. The Gazette dated 11th July 2018 talked about the amendment of the Drugs and Cosmetics Rules, 1945, in order to insert Information to be uploaded by the licensee on online portal SUGAM


    Also Read: Upload application in SUGAM as per new Rules: CDSCO issues notice

    CDSCOdrug licenceDrugs and Cosmetics Rules 1945Drugs Technical Advisory BoardDTABForm 25Form 28form 29govt of indialicencemanufacturing licencepharmapharma newspharma news indiaRule 89 drugs cosmetics RulesSugamSUGAM portal

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok